Callahan M. Wilde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Callahan M. Wilde has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Alanna L. Pyke
Stanford Department of Genetics
32 shared publications - Alex Toker
Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
32 shared publications - Alexander Meissner
Max Planck Institute for Molecular Genetics, Berlin, Germany
32 shared publications - Anne Fassl
German Cancer Research Center
32 shared publications - Anne Trinh
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
32 shared publications - Beth A. Overmoyer
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
32 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 3: Characteristics of patients with stage IV MMRd sporadic CRC from three academic Italian medical centers.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 3: Characteristics of patients with stage IV MMRd sporadic CRC from three academic Italian medical centers.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 5: Clinical course and features of patients with stage IV MMRd sporadic CRC treated with kinase inhibitors.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 5: Clinical course and features of patients with stage IV MMRd sporadic CRC treated with kinase inhibitors.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose:Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes.Experimental Design:We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69).Results:We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade.Conclusions:Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose:Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes.Experimental Design:We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69).Results:We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade.Conclusions:Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 1: Patients with MMRd sporadic CRC defined by MAPK and fusion oncogenes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 1: Patients with MMRd sporadic CRC defined by MAPK and fusion oncogenes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figures 1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Figures with Legends.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figures 1 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Figures with Legends.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 4: Clinicopathologic features of patients with stage IV disease from the main MSK cohort treated with immune checkpoint blockade.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 4: Clinicopathologic features of patients with stage IV disease from the main MSK cohort treated with immune checkpoint blockade.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 2: Patients with stage IV MMRd sporadic CRC from the main MSK cohort.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Supplemental Table 2: Patients with stage IV MMRd sporadic CRC from the main MSK cohort.
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (14) , OF1-OF11
Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose: Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes. Experimental Design: We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69). Results: We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade. Conclusions: Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (14) , OF1-OF11
Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer
Purpose: Mismatch repair–deficient (MMRd) colorectal cancers are classified based on MMR protein loss and BRAFV600E mutations. BRAF wild-type sporadic MMRd tumors exhibit a diverse landscape of alternative oncogenes, including gene fusions, with unclear biological and clinical significance. We evaluated mutually exclusive subtypes of sporadic MMRd tumors defined by oncogenic mitogen-activated protein kinase (MAPK) variants and gene fusions to determine the relationship among predominant genomic driver, MMR deficiency mechanism, and clinical outcomes. Experimental Design: We assessed 6,789 patients with colorectal cancer sequenced by MSK-IMPACT to identify 518 patients with sporadic MMRd colorectal cancer. We defined mutually exclusive oncogenic alteration subtypes and then assessed differences in allele-specific MMR-inactivating events, co-occurring oncogenic variants, and patient outcomes. We validated findings in an Italian cohort (n = 69). Results: We identify 4 sporadic MMRd colorectal cancer subtypes: (i) oncogenic fusion–positive, (ii) RAS-mutant (mut), (iii) BRAFV600E-mut, and (iv) MAPK/fusion driver–negative. These mutually exclusive subtypes were associated with conserved molecular lineages of MMR gene inactivation and WNT signaling variants. Oncogenic fusions were disproportionately prevalent in non-Caucasians, among nonsmokers, and in the transverse colon, compared with subtypes that were enriched in smokers (BRAF-mut) and male, younger patients (RAS-mut and MAPK/fusion-driverless). Oncogene-defined molecular lineages were strong predictors of patient outcomes and response to immunotherapy and tyrosine kinase inhibition for metastatic disease. Fusion-positive patients demonstrated improved survival compared with BRAF-mut cancers and benefited from immunotherapy and fusion inhibitors. MAPK/fusion driver–negative tumors were aneuploid, responded poorly to immunotherapy, and were sensitive to EGFR blockade. Conclusions: Overall, MAPK and fusion oncogenic drivers distinguish MMRd colorectal cancer molecular lineages that inform molecular and clinical phenotypes.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States